ReviewNature reviews. Drug discovery2014
REV-ERB and ROR nuclear receptors as drug targets.
Review in Nature reviews. Drug discovery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 319 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
319 citing papers in PubMed, 2 syntheses or guidelines pooled it, 570 citations in OpenAlex.
- Genetic Landscape of the ACE2 Coronavirus Receptor.Circulation · 2022Pooled it
- Systematic review of melatonin levels in individuals with complete cervical spinal cord injury.The journal of spinal cord medicine · 2020Pooled it
- Trial
- Marine n-3 polyunsaturated fatty acids slow sleep impairment progression by regulating central circadian rhythms in type 2 diabetes.Cell reports. Medicine · 2025Trial
- Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284.British journal of clinical pharmacology · 2020Trial
- BMAL1 in cardiovascular diseases: Molecular mechanisms, circadian regulation and translational perspectives (Review).Molecular medicine reports · 2026Review
- Autologous erythrocyte microparticles drive antitumour T cell immunity via haem-mediated dendritic cell activation.Nature biomedical engineering · 2026Article
- Sympathetic activation links light exposure and rest-activity rhythm to liver injury and bile acid dysregulation.Npj biological timing and sleep · 2026Article
- REV-ERB-Mediated Regulation of Neural Functional Mechanisms by Phytochemicals in the Circadian System.Nutrients · 2026Review
- Human testis-specific TTRP regulates circadian clock as an evolutionarily young natural antisense transcript of PER2.Nature communications · 2026Article
- Neuronal expression of retinoid-related orphan receptor gamma (RORγ) and revisiting its role in the central nervous system.Scientific reports · 2026Article
- RORA Targeting PRNP Modulates Age-Related Cataract via Activation Oxidative Injury-Induced Cellular Senescence and Apoptosis of Lens Epithelial Cells.Aging cell · 2026Article
- Circadian Rhythms in Acute Respiratory Distress Syndrome: Molecular Mechanisms and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Circadian clock control of breast cancer hallmarks: molecular mechanisms and therapeutic implications.Cancer metastasis reviews · 2026Review
- Quercetin and Fisetin activate circadian clock via RORα and inhibit adipocyte growth.bioRxiv : the preprint server for biology · 2026Article
- Structural optimization of drug molecules with incrementally trained language models.Nature communications · 2026Article
- Clocks on steroids: how glucocorticoid receptors tell cells the time.The Journal of endocrinology · 2026Review
- The Small Molecule SR8278 Inhibits Cell Proliferation Independent of the REV-ERB Nuclear Receptor Proteins in Human Keratinocytes.Biomolecules · 2026Article
- Neuronal expression of Retinoid-Related Orphan Receptor Gamma (RORγ) and revisiting its role in the Central Nervous System.bioRxiv : the preprint server for biology · 2026Article
- Energy-sensing molecule RORγ regulates cholesterol metabolism and immune signaling in diabetic kidney disease and aging.Nature communications · 2026Article
259 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The nuclear receptors REV-ERB (consisting of REV-ERBα and REV-ERBβ) and retinoic acid receptor-related orphan receptors (RORs; consisting of RORα, RORβ and RORγ) are involved in many physiological processes, including regulation of metabolism, development and immunity as well as the circadian rhythm. The recent characterization of endogenous ligands for these former orphan nuclear receptors has stimulated the development of synthetic ligands and opened up the possibility of targeting these receptors to treat several diseases, including diabetes, atherosclerosis, autoimmunity and cancer. This Review focuses on the latest developments in ROR and REV-ERB pharmacology indicating that these nuclear receptors are druggable targets and that ligands targeting these receptors may be useful in the treatment of several disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.